Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.
Quick V, Abusalameh M, Ahmed S, Alkoky H, Bukhari M, Carter S, Coath FL, Davidson B, Doddamani P, Dubey S, Ducker G, Griffiths B, Gullick N, Heaney J, Holloway A, Htut EEP, Hughes M, Irvine H, Kinder A, Kurshid A, Lim J, Ludwig DR, Malik M, Mercer L, Mulhearn B, Nair JR, Patel R, Robson J, Saha P, Tansley S; TOC STOP 2022 Investigators; Mackie SL. Quick V, et al. Rheumatology (Oxford). 2023 Nov 11:kead604. doi: 10.1093/rheumatology/kead604. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37952183